10x Genomics (NASDAQ:TXG) Earns Sell (E+) Rating from Weiss Ratings

2025-04-26T05:56:49Z

10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating reissued by analysts at Weiss Ratings in a research report issued to clients and investors on Thursday,Weiss Ratings reports. Several other analysts also recently commented on TXG.…

Several other analysts also recently commented on TXG. JPMorgan Chase & Co. dropped their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. UBS Group dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Citigroup reduced their price target on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Leerink Partners cut shares of 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Finally, Stifel Nicolaus lowered their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $19.79.

Get 10x Genomics alerts:

View Our Latest Analysis on TXG

10x Genomics Stock Performance

TXG opened at $8.30 on Thursday. The company has a fifty day moving average price of $9.47 and a two-hundred day moving average price of $13.11. The firm has a market capitalization of $1.02 billion, a PE ratio of -5.46 and a beta of 2.01. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $29.37.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

Insider Activity at 10x Genomics

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the transaction, the director now directly owns 61,691 shares in the company, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On 10x Genomics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co lifted its stake in shares of 10x Genomics by 60.8% during the 1st quarter. Diversified Trust Co now owns 57,236 shares of the company’s stock worth $500,000 after buying an additional 21,634 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in 10x Genomics by 9.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company’s stock valued at $271,000 after acquiring an additional 2,564 shares during the period. SG Americas Securities LLC boosted its holdings in shares of 10x Genomics by 12.8% during the first quarter. SG Americas Securities LLC now owns 82,406 shares of the company’s stock worth $719,000 after acquiring an additional 9,360 shares during the period. GAMMA Investing LLC grew its position in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after purchasing an additional 1,614 shares during the last quarter. Finally, Pallas Capital Advisors LLC bought a new position in shares of 10x Genomics during the first quarter worth approximately $208,000. 84.68% of the stock is owned by institutional investors.

About 10x Genomics

(Get Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.